(n = 3 per time point). Cmax in plasma and brain is 0.104 μg/mL and 0.097 μg/g, respectively. Tmax in plasma and brain is 1.00 h and 2.00 h, respectively. AUC 0−24h in plasma and brain is 0.650 μg·h/mL and 1.066 μg·h/g, respectively.
Materials and Methods for Supplemental Figure 1
Measurement of plasma concentration of TAK-063. Male ICR mice were supplied by supplied by CLEA Japan, Inc. (Tokyo, Japan). The mice were housed in a light-controlled room (12-h light/dark cycle, with lights on at 0700 hours). After an acclimation period of at least 1 week, mice were used at 7 weeks of age. The care and use of the animals and the experimental protocols were approved by the Institutional Animal Care and Use Committee of Takeda Pharmaceutical Company Limited.
TAK-063 was suspended in 0.5% (w/v) methylcellulose in distilled water using an ultrasonic sonicator. TAK-063 (0.3 mg/kg) was orally administered to mice with a dose volume of 20 mL/kg. Mice were decapitated 0.25, 0.5, 1, 2, 4, 8, and 24 h after administration. Trunk blood was collected into 1.5-mL centrifuge tubes. Blood samples were immediately mixed with EDTA and then centrifuged at 15000 rpm for 15 min at 4ºC. The supernatants were collected in another tube as plasma. TAK-063 concentration was measured in aliquots of mouse plasma which were mixed well with acetonitrile containing an analog of TAK-063 as internal standards and then centrifuged. TAK-063 concentrations were measured in aliquots of mouse plasma which was mixed well with acetonitrile containing an analog of TAK-063 as internal standards and then centrifuged. 
